share_log
Reuters ·  Jun 26 21:30
Tempus Receives U.S. FDA 510(K) Clearance for Tempus Ecg-Af, an AI-Based Algorithm That Identifies Patients at Increased Risk of Afib
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment